Mizuho restated their buy rating on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Thursday, AnalystRatings.com reports. They currently have a $72.00 price target on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on FGEN. BidaskClub upgraded FibroGen from a sell rating to a hold rating in a research note on Wednesday, February 5th. Zacks Investment Research upgraded FibroGen from a hold rating to a strong-buy rating and set a $48.00 price target for the company in a research note on Thursday, January 30th. Finally, ValuEngine upgraded FibroGen from a hold rating to a buy rating in a research note on Friday, January 3rd. Three analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. FibroGen currently has a consensus rating of Buy and an average target price of $51.25.
Shares of NASDAQ FGEN traded up $1.07 during midday trading on Thursday, hitting $45.58. 546,685 shares of the company’s stock were exchanged, compared to its average volume of 574,448. The company has a quick ratio of 8.95, a current ratio of 9.01 and a debt-to-equity ratio of 0.07. FibroGen has a 12 month low of $32.33 and a 12 month high of $61.23. The company’s 50 day moving average price is $43.37 and its 200 day moving average price is $42.26. The firm has a market capitalization of $3.86 billion, a PE ratio of 116.87 and a beta of 1.95.
In related news, Director Kalevi Kurkijarvi sold 6,000 shares of the business’s stock in a transaction on Monday, December 9th. The stock was sold at an average price of $47.50, for a total value of $285,000.00. Following the completion of the sale, the director now directly owns 34,400 shares in the company, valued at approximately $1,634,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Christine Chung sold 5,625 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $47.08, for a total value of $264,825.00. Following the completion of the sale, the senior vice president now owns 138,269 shares of the company’s stock, valued at $6,509,704.52. The disclosure for this sale can be found here. Insiders sold a total of 38,295 shares of company stock valued at $1,721,971 over the last 90 days. 7.83% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC raised its holdings in FibroGen by 36.1% in the 3rd quarter. Barclays PLC now owns 153,930 shares of the biopharmaceutical company’s stock valued at $5,692,000 after acquiring an additional 40,798 shares in the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of FibroGen in the 4th quarter valued at about $3,091,000. Woodstock Corp grew its position in shares of FibroGen by 119.8% in the 4th quarter. Woodstock Corp now owns 22,020 shares of the biopharmaceutical company’s stock valued at $944,000 after buying an additional 12,000 shares during the last quarter. BlackRock Inc. grew its position in shares of FibroGen by 1.0% in the 2nd quarter. BlackRock Inc. now owns 6,233,136 shares of the biopharmaceutical company’s stock valued at $281,613,000 after buying an additional 60,249 shares during the last quarter. Finally, Boston Advisors LLC grew its position in shares of FibroGen by 61.3% in the 3rd quarter. Boston Advisors LLC now owns 31,641 shares of the biopharmaceutical company’s stock valued at $1,170,000 after buying an additional 12,019 shares during the last quarter. 68.39% of the stock is owned by hedge funds and other institutional investors.
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Featured Article: Coverage Ratio
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.